MedTrace Logo

Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

NCT06435273 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-10-23

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma.

Study details include:

* The study duration for each participant will be approximately 10 weeks.
* The duration of IMP administration will be approximately 4 weeks.

Conditions

Interventions

DRUG

AZD4604

Janus kinase 1 (JAK1) inhibitor

DRUG

Placebo to AZD4604

Placebo to AZD4604

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2025-10-15
Completion
2025-10-15
FDA Drug
Yes

Countries

  • Canada
  • Denmark
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435273 on ClinicalTrials.gov